Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Patients, doctors and investors will soon learn a lot more about a new ... Eli Lilly's pill better in phase three trials because they are longer in duration than the mid-stage studies and likely ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.